Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) [EXTENSION OF 700243221]

Trial Profile

Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) [EXTENSION OF 700243221]

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2014

At a glance

  • Drugs Bosentan (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Registrational
  • Acronyms BUILD OL
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 15 Apr 2014 New trial record
    • 09 Mar 2012
    • 11 Jun 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top